Edgemont Pharmaceuticals, LLC Report issue

For profit Phase 3
Founded: Austin TX United States (2006)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2015
NCT02305797
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

lorazepam (ativan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1